共 13 条
[1]
Efficacy and safety of tadalafil for the treatment of erectile dysfunction:results of integrat- ed analyses. BROCK GB,MCMAHON CG,CHEN KK. Journal d Urologie . 2002
[2]
IC351 enhances nitric oxide-mediated relaxation of human arterial and trabecular penile smooth muscle. ANGULO J,GADAU M,FERNANDEZ A,et al. Diabetologia . 2001
[3]
IC351 (tadalafil,Cialis):update on clinical experi- ence. POBST H. Int J Impot Res,2002 .
[4]
Cellular localisation of phosphodiesterase type 11(PDE 11) in human corpus c averuosum and the contribution of PDE 11 inhibition on nerve-stimulated relaxation. BAXENDALE RW,WAYMAN CP,TURNER L,et al. J Urol,2001 .
[5]
Tadalafil-associated priapism. KING SH,HALLOCK M,STROTE J,et al. Urology . 2005
[6]
Phosphodies- terase type 11 (PDE11)cellular localisation:progress towards defining a physiological role in testis and/or reproduction. BAXENDALE RW,BURSLEM F,PHILLIPS SC. Journal d Urologie . 2001
[7]
Phosphodiester- ase 5 inhibitor profiles against all human phospho-diesterase fami- lies:implications for use as pharmacological tools. GBEKOR E,BETHELL S,FAWCETT L,et al. Journal d Urologie . 2002
[8]
Erectile dysfunction:comparison of efficacy and side effects of the PDE-5 inhibitora sildenafil, vardenafil and tadalafil-review of the literature. GRESSER U,GLEITEB CH. European Journal of Medical Research . 2002
[9]
Pharmacokinet- ics of sildenafil after single oral doses in healthy male subjects: absolute bioavailability,food effects and dose proportionality. NICHOLS DJ,MUIRHEAD GJ,HARNESS JA. Br J Clin Pharmacol,2002 .
[10]
Mechanisms of action of PDE5 inhibition in erectile dysfunction. COBBIN JD. Int J Impot Res,2004,16(Suppl I) .